Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim)

作者:法律资料网 时间:2024-07-08 22:55:08   浏览:9416   来源:法律资料网
下载地址: 点击此处下载

Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim)

State Food and Drug Administration General Administration of Customs of the People’s Republic of China


Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim)




(SFDA Decree No. 25)

The Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim), adopted by the State Food and Drug Administration, the General Administration of Customs of the People’s Republic of China and the General Administration of Sport of China, is hereby promulgated in the decree sequence number of the State Food and Drug Administration and shall come into force as of September 1, 2006.


Shao Mingli
Commissioner
State Food and Drug Administration

Mou Xinsheng
Minister
General Administration of Customs of the People’s Republic of China

Liu Peng
Minister
General Administration of Sport of China
July 28, 2006





Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim)


Article 1 The Provisions are formulated with a view to standardizing the administration of import and export of anabolic agents and peptide hormones in accordance with the Drug Administration Law of the People’s Republic of China, Customs Law of People's Republic of China, Anti-doping Regulations and other relevant laws and administrative regulations.

Article 2 The State adopts license control on the import and export of anabolic agents and peptide hormones.

Article 3 The importer shall apply for the importation of anabolic agents and peptide hormones to the State Food and Drug Administration.

Article 4 For the importation of anabolic agents and peptide hormones for medical purpose, the importers shall submit the following materials:
(1) Application Form for Drug Import;
(2) Copy of the purchasing contract or order form;
(3) Copy of the Import Drug License (or the Pharmaceutical Product License) (original or duplicate);
(4) Copy of the Drug Supply Certificate, Business License for Enterprises as a Legal Person, Qualification Certificate for Import and Export Enterprise (or Foreign Trade Operator Filing and Registration Form) and Organization Code Certificate of the importer; to import drug substance and intermediate preparations including preparations to be repackaged in China for their own needs, drug manufacturers shall submit copies of the Drug Manufacturing Certificate, Corporate Business License and Organization Code Certificate;
(5) Where holders of the Import Drug License (or the Pharmaceutical Product License) entrust other companies to export their drugs, they shall provide the authorization letter for export.

All copies mentioned above should be stamped with the official seal of the importer.

Article 5 For the importation of anabolic agents and peptide hormones for teaching and scientific research purposes, the importers shall submit the following materials:
(1) Application Form for Drug Import;
(2) Copy of the purchasing contract or order form;
(3) Certificates of legitimate qualifications of users in China, calculation basis for the quantity of the drug in use and letter of guarantee issued by the user for legitimate use and management of the drug;
(4) Approval documents for relevant scientific research projects or approval documents of relevant competent authority;
(5) Where entrusted by users for importation, importers shall provide copies of the authorization agreement, the Business License for Enterprises as a Legal Person, Qualification Certificate for Import and Export Enterprise (or Foreign Trade Operator Filing and Registration Form) and Organization Code Certificate of the importers.

All copies mentioned above should be stamped with the official seal of the importer.

Article 6 Where a enterprise in China entrusted by an overseas enterprise for contract manufacturing needs to import anabolic agents and peptide hormones, it shall provide materials required in Items (1), (3) and (5) of Paragraph 1 of Article 5, in addition, official documents to prove recorded by the local (food and) drug regulatory department of the province, autonomous region or municipality directly under the Central Government.

All copies mentioned above should be stamped with the official seal of the importer.

Article 7 The State Food and Drug Administration shall decide whether or not to approve the import within 15 working days after receiving the application for import and the relevant materials. Where the application is approved, the State Food and Drug Administration shall issue the Import License for the drug; where the application is not approved, the State Food and Drug Administration shall give reasons in writing.

Article 8 The importer may declare to the customs of the ports where drug importation is permitted upon presenting the Import License for the drug issued by the State Food and Drug Administration. The customs shall clear the drug in the presence of the Import License for the drug.
The Drug Import Note is not required for import of anabolic agents and peptide hormones.

Article 9 To import anabolic agents and peptide hormones including those sold in China for the first time for medical purpose, the importer shall fill in the Import Drug Clearance Form timely after going through the import formalities and submit the following materials in duplicate to the (food and) drug regulatory department where the port of entry is located, upon presenting the original Import Drug License (or the Pharmaceutical Product License) (original or duplicate) and the original Import License for the drug, to apply for the Notice of Import Drug Port Test:
(1) Copies of the Import Drug License (or Pharmaceutical Product License) (original or duplicate) and the Import License for the drug;
(2) Copies of the Drug Manufacturing Certificate or Drug Supply Certificate, and Copy of the Business License for Enterprises as a Legal Person.
(3) Copy of the certificate of origin;
(4) Copy of the purchasing contract;
(5) Copies of packing list, bill of lading and freight invoice;
(6) Copy of the certificate of analysis;
(7) Format of drug insert sheet, package and label (except for drug substance and intermediate preparation);

All copies mentioned above should be stamped with the official seal of the importer.

Article 10 After checking the received Import Drug Clearance Form and relevant materials, the port (food and) drug regulatory department shall return the original Import Drug License (or Pharmaceutical Product License) (original or duplicate) and the original Import License for the drug to the importer, and send the Notice of Import Drug Port Test, along with a copy of the dossier as prescribed in Article 9 of the Provisions, to the port drug testing institute on the same day.

After receiving the Notice of Import Drug Port Test, the port drug testing institute shall contact the importer within two working days and conduct sampling on the storage site. Upon the completion of the sampling, the mark “sampled” shall be stamped on the back of the first page of the original Import License for the drug, with the seal of sampling institute affixed.

Article 11 Anabolic agents and peptide hormones imported for teaching and research purposes or for the domestic manufacturing contracted by overseas enterprises are exempted from testing.

Article 12 The port (food and) drug regulatory department shall report timely to the State Food and Drug Administration in any of the following circumstances:
(1) The port (food and) drug regulatory department refuses to issue the Notice of Import Drug Port Test in accordance with the provisions in Article 17 of the Provisions for Import Drug (Decree No. 4 of the State Food and Drug Administration and the General Administration of Customs);
(2) The port (food and) drug testing institute refuses the sampling in accordance with the requirements in Article 25 of the Provisions for Import Drug.

The port (food and) drug regulatory department shall take mandatory administrative measures to seal up or seize all the imported drugs within the situations prescribed in the previous paragraph. It shall make the decision of allowing shipping back within seven days from the date of the seal-up or seizure, and inform the importer of applying for the Export License for the drug according to the export procedures for anabolic agents and peptide hormones prescribed in the Provisions and return all the import drugs to the original exporting country.

Where the importer fails to respond or make clear its intention to ship back the drugs within ten days after being informed of the decision, the sealed up or seized drugs shall be destroyed under the supervision of the port (food and) drug regulatory department.

Article 13 For imported anabolic agents and peptide hormones out of specifications upon testing by the port drug testing institute, the importer shall provide a detailed report about the distribution and use of all the imported drugs to the port (food and) drug regulatory department where the importer is located within two days after receiving the Import Drug Test Report.

After receiving the Import Drug Test Report, the port (food and) drug regulatory departments shall take mandatory administrative measures to timely seal up or seize all the drugs and, within seven days, decide whether or not to place the case on file.

Where the importer fails to apply for a retesting within the specified timeline or the result of the retesting is still out of specifications, the port (food and) drug regulatory department shall make the decision of allowing shipping back and notify the importer to apply for the Export License for the drug according to export procedures for anabolic agents and peptide hormones prescribed in the Provisions to return all the imported drugs to the original exporting country. Where the importer fails to respond or make clear its intention to ship back the drugs within ten days from the date of receiving the decision, the drugs shall be destroyed under the supervision of the port (food and) drug regulatory department.

Where the result of retesting is in compliance with the specifications, the port (food and) drug regulatory department shall remove the mandatory administrative measures of seal-up and seizure.

The port (food and) drug regulatory department shall handle the case according to the provisions in Paragraph 2, Paragraph 3 and Paragraph 4 of this Article and report the result to the State Food and Drug Administration, and, at the same time, notify the (food and) drug regulatory departments of provinces, autonomous regions and municipalities directly under the Central Government as well as other port (food and) drug regulatory departments.

Article 14 Where domestic drug manufacturers, distributors and medical institutions purchase imported anabolic agents and peptide hormones, the supplier shall provide copies of the Import Drug License (or Pharmaceutical Product License), the Import License for the drug and the Import Drug Test Report, and affix its official seal to the abovementioned copies.

Article 15 The exporter shall apply for exportation of anabolic agents and peptide hormones to the (food and) drug regulatory department of the province, autonomous region or municipality directly under the Central Government, where it is located, and submit the following materials:
(1) Application Form for Drug Export;
(2) Original import permit (or its copy with notarization) provided by the drug regulatory authority of the importing country or region.
If the importing country or region has no license system in the importation of anabolic agents and peptide hormones, the exporter shall provide the official document (original) of the drug regulatory authority of the importing country or region to prove that the import of the drugs of this type is exempted from the import permit, along with one of the following documents:
a. Original official document (or its copy with notarization) granting import provided by the drug regulatory authority of the importing country or region;
b. Certificates of legitimate qualifications of importers and original supporting document (or its copy with notarization) proving legitimate use of the drug;
(3) Copy of the purchasing contract or order form (except for manufacturers that export their own products);
(4) Copy of the export contract or order form;
(5) Where the export drug is an approved one produced by a domestic manufacturer, the Drug Manufacturing Certificate and Business License for Enterprises as a Legal Person of the manufacturer and a copy of the approval document of the drug shall be provided;
Where the export drug is produced by a domestic enterprise under contract of an overseas enterprise, the exporter shall provide a copy of the official document to prove recorded by the local (food and) drug regulatory department of the province, autonomous region and municipality directly under the Central Government.
(6) Copies of the Business License for Enterprises as a Legal Person, Qualification Certificate for Import and Export Enterprise (or Foreign Trade Operator Filing and Registration Form) and Organization Code Certificate of the exporter.

All copies mentioned above should be stamped with the official seal of the exporter.

Article 16 Where the drugs are to be shipped back in accordance with the requirements in Article 12 and Article 13 of the Provisions, the exporter shall provide the following materials to apply for the Export License for the drug:
(1) Documents proving the request for return of goods made by the original exporter of the exporting country;
(2) Import License for the drug.

Article 17 The (food and) drug regulatory department of the province, autonomous region and municipality directly under the Central Government shall decide whether or not to approve the export within 15 working days after receiving the export application and relevant materials.

Where the application is approved, the regulatory department shall issue the Export License for the drug; where the application is not approved, the regulatory department shall give reasons in writing.

Where the Export License for the drug is applied for in accordance with the requirements in Article 16 of the Provisions, the issuing authority shall mark “return of the original goods” on the Export License for the drug.

Article 18 The exporter may go through the customs formalities upon presenting the Export License for the drug issued by the (food and) drug regulatory department of the province, autonomous region and municipality directly under the Central Government. The customs shall clear the drug in the presence of the Export License for the drug.

Article 19 The importer and exporter shall provide one more sheet of customs declaration form and apply for sign-back of the sheet when going through the customs formalities. The customs shall stamp the “proof seal” on the sheet in the presence of the Import License for the drug and Export License for the drug. The customs shall charge the cost according to the relevant regulations for issuing certificates.

The importer and exporter shall return the first sheet of the Import License for the drug or Export License for the drug along with the customs declaration form with the seal of the customs, to the issuing regulatory department within one month after completing the import and export.

Where the importer or exporter conducts no relevant importation or exportation after obtaining the Import License for the drug and Export License for the drug, the importer or exporter shall return the original license to the issuing regulatory department within one month after expiration of the license.

Article 20 The validation of the Import License for the drug is one year; the validation of the Export License for the drug is no more than three months (valid within the calendar year).

“One license for one customs clearance” is implemented for the Import License for the drug and Export License for the drug. The license shall be used only once within the validation and its content shall not be altered. Where the import or export is postponed for some reasons, the importer or exporter may request for a new license once with the original one.

Article 21 Where the Import License for the drug or Export License for the drug is lost, the importer or exporter shall report the loss to the original issuing authority in writing immediately. After receiving the loss report, the original issuing authority shall notify the port customs and reissue the license if no harmful consequences are found through confirmation.

Article 22 The Import License for the drug and Export License for the drug are uniformly printed by the State Food and Drug Administration.

Article 23 Where anabolic agents and peptide hormones are imported or exported in the form of processing trade, the customs shall go through and supervise the clearance formalities upon presentation of the Import License for the drug or Export License for the drug. Those not exported for special reasons shall be transferred to and handled by the local (food and) drug regulatory department in accordance with relevant regulations, and the customs shall conduct the verification and cancellation procedures in the presence of relevant documents.

Article 24 Anabolic agents and peptide hormones entering or leaving between bonded zones, export processing zones, other special Customs controlling areas, Customs bonded and controlling areas, with overseas, or between the special Customs controlling areas and the Customs bonded and controlling areas are exempt from application for the Import License for the drug or Export License for the drug, and supervised by the Customs.

Import License for the drug shall be applied for anabolic agents and peptide hormones entering from bonded zones, export processing zones, other special Customs controlling areas and Customs bonded and controlling areas into other places in China.

Export License for the drug shall be applied for anabolic agents and peptide hormones entering bonded zones, export processing zones, other special Customs controlling areas and Customs bonded and controlling areas from other places of China.

Article 25 Where an individual carries or mails anabolic agents and peptide hormones, within a reasonable amount, into or out of China for medical needs, the customs shall clear the drugs in the presence of prescriptions of medical institutions in accordance with relevant regulations on prescriptions of the competent health department.

Article 26 Besides prescribed in the Provisions, the importation, port test, supervision and control of anabolic agents and peptide hormones for medical purpose are implemented with reference to requirements related to drug importation in the Provisions for Drug Importation.

Article 27 Anabolic agents and peptide hormones imported for medical purpose mentioned in the Provisions refer to the import anabolic agents and peptide hormones to be used for preparation production or to be marketed in China.

Importer refers to the importer specified on the Import License for the drug obtained in accordance with the Provisions.

Exporter refers to the exporter specified on the Export License for the drug obtained in accordance with the Provisions.

Article 28 These Provisions shall go into effect as of September 1, 2006. The Notice on Import and Export of Anabolic Agents and Peptide Hormones (Guo Shi Yao Jian An [2004] No. 474) issued by the State Food and Drug Administration on September 30, 2004 shall be annulled therefrom.


下载地址: 点击此处下载

关于修改《湖南省野生动植物资源保护条例》的决定

湖南省人大常委会


关于修改《湖南省野生动植物资源保护条例》的决定
   

湖南省第十届人民代表大会常务委员会公告第27号

  《湖南省人民代表大会常务委员会关于修改〈湖南省野生动植物资源保护条例〉的决定》于2004年7月30日经湖南省第十届人民代表大会常务委员会第十次会议通过,现予公布,自公布之日起施行。

湖南省第十届人民代表大会常务委员会第十次会议决定对《湖南省野生动植物资源保护条例》作如下修改:
第二十二条修改为:“运输、邮寄、携带重点保护的野生动物及其产品出县境的,应当凭有关证件,向所在地的县级人民政府的林业行政主管部门提出申请,报省林业行政主管部门或者其授权的单位核发运输证明。
“在省内运输有益的或者有重要经济、科学研究价值的野生动物及其产品的,由起运地的县级以上人民政府的林业行政主管部门核发运输证明;运输出省的,由省林业行政主管部门或者其授权的单位核发运输证明。
“外省过境运输野生动物及其产品的,凭起运省的运输证明和进入我省的过境签证通行。”
本决定自公布之日起施行。
《湖南省野生动植物资源保护条例》根据本决定作相应修正,重新公布。


提高举报线索初查成案率之管见

胡立柱


从某市检察机关召开的工作会议得知,该市去年立案查处贪污贿赂、挪用公款案件数只占举人举报中心移送初查线索的4%。成案率低的问题,不仅影响了检察机关的自身形象,而且制约着检察工作的深入开展。举报线索初查成案率低,既有初查的法律地位不明确、立案观念陈旧、举报线索本身价值不高、管理机制不健全、科技含量低等客观方面的原因,也存在审查线索不细致、分流线索不及时、初查不规范、全局观念淡薄、工作主动性不够等主观方面的原因。针对上述问题,结合工作实践,笔者认为提高成案率应从以下几个方面着手:

一、明确初查的法律性质,完善初查机制。
我国《刑事诉讼法》第八十六条规定立案的条件是“认为有犯罪事实需要追究刑事责任的时候,应当立案”,而对初查却没有明文规定。为了提高初查工作的地位,同时为了加强对初查工作的领导,最高人民检察院在《人民检察院刑事诉讼规则》(下称《规则》)中对初查作了专节规定,并对初查提出两条基本原则,即:举报线索的初查,由检察长或检察委员会决定;在初查过程中,不得对被调查对象采取强制措施。进而在1999年高检院发布了《关于检察机关反贪污贿赂工作若干问题的决定》(下称《决定》),界定“初查是检察机关对案件线索在立案前依法进行的审查,包括必要的调查。”但是由于初查工作的非法定性,以及由此带来的手段有限性,在实践中制约了初查工作的开展。所以,建议在法律中必须明确初查的法律地位。初查实质上是一般性的调查活动和审查,它是后续侦查的前奏,是立案的基础。只有对初查的法律性质作出界定,才能使初查有法律依据。法律地位明确了,才能规范初查行为,避免在初查阶段滥用强制措施,减少违法违纪现象,提高初查效率,防止有价值的线索流失。
二、更新立案观念。
公安机关侦查工作的开展一般是“从事到人”,与此的不同的是,贪污贿赂犯罪、挪用公款等案件,一般很少有现场可查,举报又不及时,并且犯罪分子往往具有较强的反侦查能力。这使检察机关在工作中形成了“从人到事”的主导型侦查模式,排斥了“以事立案”的实效性,致使立案数量少。为此,需要更新立案观念,第一,要改“以人立案”为主为“以人立案”与“以事立案”并重。在特定条件下要根据案件情况,果断“以事立案”,从而避免对犯罪分子和犯罪行为“漏侦”。这也适应高检院提出的检察改革的要求。第二,放宽程序。根据刑诉法第十二条:“未经人民法院依法判决对任何人都不得确定有罪”的规定可知,在立案阶段不能随意确定犯罪嫌疑人是否有罪,立案的实体意义越来越淡化,而程序意义越来越突出。《决定》也指出“根据案件的具体情况,符合立案条件的,可以直接立案。”由此可见,立案不需要以确凿的犯罪事实为基础,我们要注意避免出现立案与逮捕条件同一,甚至更高的不协调情形。只有在初查阶段,根据案情的发展,不断地收集、固定证据,才能提高成案的实效。这也符合刑诉法放宽程序要求的总趋势。
三、推行密码举报,提高举报线索质量。
据报载,全国检察机关受理的举报线索中,署名举报仅占10%。署名举报少,匿名举报多,举报线索本身价值不高,是造成成案率低的重要原因。因此必须着力提高举报线索质量。密码举报是一种新的署名举报方法,是一种专门工作与群众路线相结合的有效形式。《人民检察院举报工作的规定》,密码举报由举报中心专人负责,并设立密码举报专线和自动受理系统,统一受理、审查密码举报材料。河南省新乡市新华区检察院在全国率先试行密码举报,成案率提高了近10%。密码举报不仅可减轻举报人的心理压力,鼓励群众同职务犯罪作斗争,在一定程度上保证举报内容的真实性,而且还可减少重复、越级举报,避免国家机关重复劳动,提高查办案件的质量,推动反腐败斗争的深入健康发展,应在各级检察机关大力推行。
四、健全管理机制。
有些检察机关对查处职务犯罪工作进行了量化管理,但却不够合理。如,规定完成一件初查的给3分,对移送立案的仅在完成初查的基础上加3分。而立案自然要比一般性调查投入更多的人力和物力,侦查和诉讼过程也比较复杂。这势必造成对能否立案重视程度不够,导致成案率较低。为此,应充分认识到初查是查办案件的第一道程序,是初始环节,应十分重视成案意识,不能以查销、消化线索为目的,在量化管理中,可适当增加移送立案的分值,为提高成案率提供科学合理的机制。
五、加大办案的科技含量。
先进的科技成果 在造福人类的同时,也被一些犯罪分子所利用,他们在作案后或被检察机关调查后,便迅速串供、毁证。传统的侦查手段已适应不了侦破案件的需要。因此,要树立适用现代化技侦手段破案的思想。要逐步建立多层次的办案经费保障机制,增加对交通、通讯、录音录象等办案设备的投入,开发适用于反贪污贿赂系统案件管理、指挥协调、侦查效率管理、信息通报、信息共享的计算机管理体系,逐步实现检察系统的计算机联网,增强办案的科技含量,不断提高侦查工作的现代化水平。
六、加强举报线索审查评估,筛选出真正有价值的线索进行重点侦查。
要增强线索分流的科学性和准确性,提高线索利用价值,应将案件线索分类管理、重点评估、及时分流。对接到举报的一般案件线索,逐件登记后,坚持用“统一审查、统一分流、统一协调”的标准,规范案件线索初查;对有价值的线索,实行案件线索评估、评议制度,及时召开评估会议,由检察长或分管检察长负责决定重要线索的分流,并抽调业务素质强的干警迅速展开初查,力争突破案件。实践证明,这是一种行之有效的措施。据某院统计,去年初查成案率比以前高出了近十三个百分点。
七、从规范办案行为入手,提高办案质量,迅速侦破案件。
实行“案前准备会”制度,为提高办案质量打下坚实基础。规定所有案件在初查前必须召开案前准备会,精心制订初查方案。从根本上克服初查的随意性和盲目性,使每件案件都做到有备而查、有的放矢。开展初查工作,不能将破案的希望寄托在犯罪嫌疑人的口供上,而应十分注重初查手段,初查中要突出一个“秘”字,围绕“秘”字全面收集、固定证据;立案要讲究一个“快”字,符合立案条件的,在固定证据、审核证据的基础上要迅速立案,实现初查向侦查的转换,进而积极运用各种强制措施和侦查手段,全力侦破案件,使侦查机关始终处于一种主动的地位,从而保证案件质量,提高成案率。
八、向初查人员专职化过渡,充分发挥个人主观能动性,全力突破案件。
现在各级检察机关往往人手相对缺乏,更为主要的是,案件初查的专业化程度要求相对较高,由于初查人员未实现专门化、专业化,初查时多为一般性调查,泛泛了解一下情况,然后草草地结案,必然导致初查成案率低。因此要逐步向初查人员专职化过渡,办案人员要发挥主观能动性,主动出击,通过深挖细查来查明案件情况,并全面收集、固定证据,发现犯罪事实,揭露和打击犯罪。   
九、增强大局意识,树立检察机关自身良好形象。
要全面认识初查工作的重要性,初查的成功与否,在一定程度上决定着检察机关在群众心目中的形象和地位。对群众的举报线索不能草草初查了事,不能只求数量,不求质量,缺乏大局意识。同时也应注意避免侦查权的滥用,在初查过程中不得对被查对象采取强制措施,不得查封、扣押、冻结被查对象的财产。